Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas

被引:49
|
作者
Niijima, M
Yamaguchi, T
Ishihara, T
Hara, T
Kato, K
Kondo, F
Saisho, H
机构
[1] Chiba Univ, Dept Med 1, Sch Med, Chiba, Japan
[2] Chiba Univ, Dept Pathol 2, Sch Med, Chiba, Japan
关键词
intraductal papillary-mucinous tumor of the pancreas; cyclooxygenase-1 (COX-1); cyclooxygenase-2 (COX-2); proliferating cell nuclear antigen; immunohistochemistry; in situ hybridization;
D O I
10.1002/cncr.10358
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The objective of this study was to investigate COX-2 expression in intraductal papillary-mucinous tumor of the pancreas (IPMT) using immunohistochemical staining (111) and in situ hybridization (ISH). METHODS. Immunohistochemical staining of COX-2 was performed using samples from 42 patients with IPMT (hyperplasia, 10; adenoma, 13; noninvasive adenocarcinoma, 13; invasive adenocarcinoma, 6) and from 10 patients with ductal pancreatic adenocarcinoma, 10 with chronic pancreatitis, and 6 normal pancreatic tissues as controls. Also, COX-2 was determined in five patients with IPMT noninvasive adenocarcinoma, in whom all histologic types, hyperplasia, adenoma, and adenocarcinoma were observed in the same excised specimens. Furthermore, Ill of proliferating cell nuclear antigen (PCNA) was performed, and the labeling index (LI) was calculated to investigate the correlation with COX-2. To confirm COX-2 mRNA, the authors performed ISH in 20 IPMT patients. RESULTS, COX-2 was positive in 0%, 0%, and 10% of pancreatic duct epithelial cells from normal pancreatic tissue, chronic pancreatitis, and IPMT hyperplasia, respectively. Whereas it was positive in 69%, 77%, 67%, and 80% of IPMT adenoma, IPMT noninvasive adenocarcinoma, IPMT invasive adenocarcinoma, and ductal pancreatic adenocarcinoma, respectively, showing significant differences between IPMT hyperplasia and IPMT adenoma or IPMT adenocarcinoma (noninvasive and invasive adeno carcinoma). In the same patient, COX-2 was negative in the hyperplasia region but positive in adenoma and adenocarcinoma regions, showing results reflecting the progression of the disease. In the COX-2 negative group, PCNA-LI was 19.2 +/- 17.9%, and 33.5 +/- 15.7% in the positive group, a significant difference. On ISH COX-2 mRNA was expressed in three of four and seven of eight COX-2 positive patients with IPMT adenoma and adenocarcinoma, respectively CONCLUSIONS. COX-2 was highly expressed in adenoma and adenocarcinoma in IPMT, showing a relation to the histologic grade of IPMT. (C) 2002 American Cancer Society.
引用
收藏
页码:1565 / 1573
页数:9
相关论文
共 50 条
  • [31] Mucin expression profile is related to biological and clinical characteristics of intraductal papillary-mucinous tumors of the pancreas
    Ito, H
    Endo, T
    Oka, T
    Matumoto, T
    Abe, T
    Toyota, M
    Imai, K
    Satoh, M
    Maguchi, H
    Shinohara, T
    PANCREAS, 2005, 30 (04) : E96 - E102
  • [32] Preoperative diagnosis of intraductal papillary-mucinous tumors of the pancreas with attention to telomerase activity
    Inoue, H
    Tsuchida, A
    Kawasaki, Y
    Fujimoto, Y
    Yamasaki, S
    Kajiyama, G
    CANCER, 2001, 91 (01) : 35 - 41
  • [33] INTRADUCTAL PAPILLARY-MUCINOUS NEOPLASM OF THE PANCREAS - A CLINICOPATHOLOGICAL ENTITY
    SANTINI, D
    CAMPIONE, O
    SALERNO, A
    GULLO, L
    MAZZOLENI, G
    LEONE, O
    MARTINELLI, G
    MARRANO, D
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 1995, 119 (03) : 209 - 213
  • [34] Surgical Indications for Intraductal Papillary-Mucinous Neoplasm of the Pancreas
    Watarai, Y.
    Shimamura, H.
    Takeda, K.
    PANCREAS, 2009, 38 (08) : 1060 - 1060
  • [35] Histologic and immunohistochemical comparison of intraductal tubular carcinoma, intraductal papillary-mucinous carcinoma, and ductal adenocarcinoma of the pancreas
    Tajiri, T
    Tate, G
    Kunimura, T
    Inoue, K
    Mitsuya, T
    Yoshiba, M
    Morohosh, T
    PANCREAS, 2004, 29 (02) : 116 - 122
  • [36] Clinicopathologic view of intraductal papillary-mucinous tumor of the pancreas
    Klöppel, G
    HEPATO-GASTROENTEROLOGY, 1998, 45 (24) : 1981 - 1985
  • [37] Treatment strategy of intraductal papillary-mucinous tumor of the pancreas
    Kenji Yamao
    Journal of Gastroenterology, 2005, 40 : 773 - 774
  • [38] Treatment strategy of intraductal papillary-mucinous tumor of the pancreas
    Yamao, K
    JOURNAL OF GASTROENTEROLOGY, 2005, 40 (07) : 773 - 774
  • [39] Molecular genetics of intraductal papillary-mucinous neoplasms of the pancreas
    Furukawa, Toru
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY, 2007, 14 (03): : 233 - 237
  • [40] MRCP Imaging of Intraductal Papillary-Mucinous Neoplasm of the Pancreas
    Kantarci, Mecit
    Bayraktutan, Ummugulsum
    Yilmaz, Omer
    Karatas, Dilek
    EURASIAN JOURNAL OF MEDICINE, 2012, 44 (01): : 61 - 62